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Edited by Gerrit van MeerAbstract Niemann-Pick C (NPC) disease is a progressive neu-
rological disorder in which cholesterol, gangliosides and bis-mon-
oacylglycerol phosphate accumulate in late endosomes/
lysosomes. This disease is caused by mutations in either the
NPC1 or NPC2 gene. NPC1 and NPC2 are involved in egress
of lipids, particularly cholesterol, from late endosomes/lysosomes
but the precise functions of these proteins are not clear. An
important question regarding the function of NPC proteins is:
why do mutations in these ubiquitously expressed proteins have
such dire consequences in the brain? This review summarizes
the roles of NPC proteins in lipid homeostasis particularly in
the central nervous system.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Niemann-Pick type C (NPC) disease is an autosomal reces-
sive lipidosis that is characterized by progressive neurodegen-
eration [1]. This disorder is caused by a mutation in either
the NPC1 gene (in 95% of the cases) or the NPC2 gene (in
5% of the cases). NPC disease is biochemically distinct from
Niemann-Pick disease types A and B which are caused by ge-
netic defects in lysosomal sphingomyelinase activity [2]. The
clinical manifestations of NPC disease (vertical gaze palsy,
ataxia, dystonia and seizures) usually become evident in early
childhood and death typically occurs in the teenage years.
Many NPC infants also experience neonatal jaundice and
enlargement of the liver and/or spleen and a few of these indi-
viduals die from acute liver failure. Currently, no eﬀective
treatment is available for NPC disease. Although NPC disease
is relatively rare (1 in 150000 live births in the general pop-
ulation), the incidence in Yarmouth County, Nova Scotia is
1% with an estimated carrier frequency of 10–25% [3]. The
most characteristic histological features of the brains of indi-
viduals with NPC disease are neuronal loss, particularly of
Purkinje cells in the cerebellum, and the widespread appear-
ance of swollen neurites [4]. The biochemical phenotype of
NPC-deﬁcient cells and tissues is the lysosomal accumulation*Fax: +1 780 492 3383.
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doi:10.1016/j.febslet.2006.06.008of cholesterol [5,6] and other lipids, including bis-monoacyl-
glycerol phosphate [7] and the gangliosides GM2 and GM3
[8–10].
The brain is the most cholesterol-rich organ in the body:
approximately 25% of the body’s cholesterol is located in the
brain whereas the brain comprises only 5% of body mass.
In most tissues, cholesterol is acquired either from endogenous
synthesis or from receptor-mediated endocytosis of plasma
lipoproteins, particularly low density lipoproteins (LDLs).
However, cholesterol metabolism in the central nervous system
(CNS) is distinct from that in peripheral tissues because plas-
ma lipoproteins are unable to cross the blood–brain barrier.
Therefore, all cholesterol in the brain is synthesized within
the CNS [11]. The majority (70–80%) of cholesterol in the
brain of adult animals resides in myelin. The highest rate of
cholesterol synthesis in the brain occurs during the period of
active myelination after which cholesterol synthesis declines
to a low level that is thought to reﬂect primarily that occurring
in neurons and astrocytes [12]. The half-life of cholesterol in
the brain is 4–6 months. In the face of ongoing synthesis of
cholesterol in the brain, cholesterol homeostasis is maintained
by the export of excess cholesterol in the form of 24-hydroxy-
cholesterol from the brain into the plasma. This derivative of
cholesterol is produced by the action of cholesterol 24-hydrox-
ylase, an enzyme that is expressed only in a speciﬁc subset of
neurons [13]. Interestingly, in NPC disease cholesterol accumu-
lates in all tissues except the brain. Indeed, in NPC-deﬁcient
brains the amount of cholesterol even decreases with increasing
age [14]. The reason that cholesterol does not accumulate in
NPC-deﬁcient brains is probably because extensive demyelina-
tion occurs in this disease [15]. Since myelin is the major source
of cholesterol in the brain, the progressive loss of myelin would
be expected to mask any age-related increase in the cholesterol
content of neurons and astrocytes [16].2. Two NPC genes in mammalian cells
The human NPC1 gene was identiﬁed and cloned in 1997
[17]. The NPC1 protein is an integral membrane protein that
is primarily localized to late endosomes/lysosomes but also cy-
cles through the Golgi apparatus [18,19]. This protein contains
1278 amino acids and 13 putative transmembrane domains
that are separated by lumenal glycosylated loops (Fig. 1).
NPC1 also contains a cysteine-rich loop [20], a di-leucine lyso-
somal targeting motif and a leucine zipper motif, the latter
suggesting that NPC1 interacts with other proteins [21]. One
candidate as a NPC1-interacting protein was MLN64, ablished by Elsevier B.V. All rights reserved.
Fig. 1. Topological model of NPC1 protein. NPC1 is a 1278-amino acid transmembrane protein that is present in late endosomal/lysosomal (LE/lys)
membranes. The lumenal N-terminus of the protein contains a leucine zipper motif whereas the C-terminus is cytosolic and contains a lysosomal
targeting sequence. The protein is predicted to contain 13 transmembrane domains, ﬁve of which (red bars enclosed in red box) comprise a sterol-
sensing motif.
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a START domain that has been identiﬁed in some lipid trans-
port proteins [22]. However, mice with a targeted mutation in
MLN64 are healthy and display only minor problems in sterol
traﬃcking [23], suggesting that MLN64 is not an obligatory
component of the NPC1 pathway. An important feature of
the NPC1 protein is the ﬁve transmembrane domains that
comprise a sterol-sensing domain (Fig. 1) [17,24]. This motif
has been identiﬁed in other proteins that are involved in
cholesterol homeostasis, such as the sterol regulatory ele-
ment-binding protein cleavage activating protein (SCAP) and
3-hydroxy-3-methylglutaryl-Co-A reductase.
The NPC2 gene (also called HE1) was identiﬁed in a study
designed to characterize the lysosomal proteome [25]. The
151 amino acid NPC2 protein is a ubiquitously expressed, sol-
uble protein that is present in the lumen of lysosomes. This
cholesterol-binding protein had previously been identiﬁed as
a major secretory component of epididymal ﬂuid [26]. The
crystal structure of NPC2 has been solved and reveals a hydro-
phobic binding pocket that has the capacity to bind cholesterol
[27,28]. The disease progression in patients with genetic defects
in NPC2 appears to parallel that of individuals who are deﬁ-
cient in NPC1 [29,30]. Although the properties of NPC1 and
NPC2 have been extensively investigated, the precise function
of neither of these proteins has yet been deﬁned.
Investigation of the function of NPC1 and NPC2 has been
greatly aided by the development of cell and animal models
of NPC deﬁciency. These model systems include mutants of
yeast [31] and Drosophila [32], skin ﬁbroblasts from NPC pa-
tients [5,6], and mutants of Chinese hamster ovary cells deﬁ-
cient in NPC1 [33,34]. Two murine models of NPC disease,
that have null mutations in the Npc1 gene, are widely used
[35,36]. These mice are asymptomatic at birth but progressively
develop neurological problems typical of those in human NPC
disease. These mice usually die by the age of 10–15 weeks. A
feline model with a spontaneous mutation in NPC1 has also
been used for some studies [37]. More recently, a hypomorphic
mouse expressing only 0–4% of residual NPC2 protein was
generated. The progression of neurological symptoms and
the lipid accumulation in Npc1/ mice and Npc2-hypomor-
phic mice, as well as in double mutants deﬁcient in both
NPC proteins, are essentially identical suggesting that NPC1
and NPC2 participate in the same lipid transport pathway.
Other useful tools for studying the phenotype of NPC-deﬁ-
ciency in cultured cells are the amphiphilic amines U18666A
and imipramine [38–40], as well as progesterone [41,42] andthe steroidal analog GW707 [43]. These compounds mimic
NPC1 deﬁciency in many respects including the sequestration
of cholesterol in late endosomes/lysosomes. However, not all
of the biochemical eﬀects of NPC1 deﬁciency are recapitulated
by these agents [44]. For example, in addition to causing cho-
lesterol sequestration in late endosomes/lysosomes, U18666A
also inhibits cholesterol biosynthesis at the level of squalene
epoxidase [45].3. NPC proteins are required for the egress of cholesterol from
late endosomes/lysosomes
The accumulation of large amounts of unesteriﬁed choles-
terol in late endosomes/lysosomes of NPC1-deﬁcient ﬁbro-
blasts that have been loaded with LDL-cholesterol implies
that NPC1 is involved in the movement of LDL-derived, une-
steriﬁed cholesterol out of the endosomal pathway [5,6]. This
idea is supported by the ﬁnding that the NPC1 protein con-
tains a sterol-sensing motif [17]. The intracellular itinerary of
LDL-derived cholesterol transport, and the proposed site of
action of NPC1 in this pathway, are illustrated in Fig. 2.
Exogenously-supplied LDLs are endocytosed by the LDL
receptor that is concentrated within clathrin-coated pits on
the cell surface. Upon reaching the late endosomes/lysosomes,
cholesteryl esters within the core of the LDL particles are
hydrolyzed to unesteriﬁed cholesterol. Subsequently, in an
NPC1-dependent pathway, the released cholesterol leaves the
late endosomes/lysosomes and is distributed to other mem-
branes including the plasma membrane and the endoplasmic
reticulum.
Available data are consistent with the idea that NPC1 and
NPC2 participate together in mediating the egress of choles-
terol from the late-endosomes/lysosomes although the precise
mechanism by which these proteins act remains unknown.
Based on known motifs in the protein, and from functional
studies on mutant forms of NPC1, several roles have been pro-
posed for NPC1 [46–49] including: a cholesterol ‘‘ﬂippase’’, a
fatty acid permease, a ganglioside transporter, a cholesterol
sensor that monitors the level of cholesterol in the lysosomal
membrane and promotes the release of cholesterol from the
membrane to an acceptor carrier protein, and a member of a
multi-protein complex that mediates cholesterol movement
out of lysosomal membranes. Some recent studies have sug-
gested that NPC2 might function directly as a cholesterol
transport protein [50]. NPC2 is a soluble intra-lysosomal
Fig. 2. NPC1 is required for the egress of low density lipoprotein
(LDL)-derived cholesterol from late endosomes/lysosomes. (1) LDL is
(2) endocytosed by LDL receptors that are clustered in coated pits on
the cell surface. (3) In late endosomes/lysosomes (LE/lys) cholesteryl
esters in LDLs are hydrolyzed to unesteriﬁed cholesterol which is
distributed throughout the cell (4), particularly to the plasma mem-
brane via an unknown mechanism that requires NPC1. (5) Cholesterol
from the late endosomes/lysosomes is also transported to the endo-
plasmic reticulum (ER) where an increased cholesterol content results
in decreased synthesis of cholesterol and LDL receptors, and increased
cholesterol esteriﬁcation. In addition, cholesterol that is synthesized in
the ER is transported to the plasma membrane (6). In NPC1-deﬁcient
cells, unesteriﬁed cholesterol becomes sequestered in late endosomes/
lysosomes so that the cholesterol content of the plasma membrane is
reduced. Moreover, despite an overall accumulation of cholesterol in
NPC1-deﬁcient cells, the endoplasmic reticulum does not sense the
increased cholesterol content in the cell. Consequently, the synthesis of
cholesterol and LDL receptors continues unabated and cholesterol
esteriﬁcation is inappropriately decreased.
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shown in an in vitro transport assay that NPC2 transports
cholesterol to phospholipid vesicles via a direct interaction
with acceptor membranes. Intriguingly, this transfer is pro-
moted by inclusion of the lysosomal phospholipid, bis-mono-
acylglycerol phosphate, in the acceptor membranes [50].
Possibly NPC1 acts in concert with NPC2 so that NPC1 is a
cholesterol ‘‘sensor’’ whereas NPC2 acts as a cholesterol trans-
porter. However, it is not clear how the presence of the NPC2
protein within the lumen of late endosomes/lysosomes would
be able to fulﬁll this role.
A consequence of the sequestration of cholesterol in lyso-
somes of NPC1-deﬁcient cells is that the cholesterol content
of the plasma membrane is reduced [51]. Thus, despite an over-
all accumulation of cholesterol in NPC1-deﬁcient cells, the
endoplasmic reticulum does not sense the increased cholesterol
content in the cell. Consequently, the synthesis of cholesterol
and LDL receptors continues unabated and cholesterol esteri-
ﬁcation is inappropriately decreased (reviewed in [52]). It was
originally thought that the cholesterol that accumulates in
NPC1-deﬁcient cells was derived only from LDLs internalized
by receptor-mediated endocytosis. However, endogenously
synthesized cholesterol also appears to become sequestered in
the endosomal pathway of NPC1-deﬁcient ﬁbroblasts [53].
Furthermore, in NPC1-deﬁcient neurons, newly-synthesized
cholesterol appears to be the major source of the cholesterol
that accumulates in the late endosomes/lysosomes of cell
bodies [44]. The accumulation of newly-made cholesterol in
the endosomal system would not be unexpected since the plas-
ma membrane, the site of most cellular cholesterol, is con-
stantly undergoing endocytosis.4. NPC1 deﬁciency leads to defects in vesicle traﬃcking
Loss of NPC1 function appears to have profound eﬀects on
multiple vesicle transport processes. For example, NPC1 deﬁ-
ciency results in the formation of multilamellar vesicles that
are enriched in cholesterol, glycosphingolipids and bis-mono-
acylglycerol phosphate [7]. In addition to the formation of
lipid-laden endosomes, NPC1-deﬁcient ﬁbroblasts exhibit
reduced mobility of endosomal tubulovesicular structures
[54]. The traﬃcking of mannose-6-phosphate receptors is also
impaired in NPC1-deﬁcient cells [7]. In a recent study, the ef-
fect of cholesterol sequestration in late endosomes/lysosomes
on Rab9-dependent export of mannose-6-phosphate receptors
was investigated [55]. NPC1 deﬁciency was found to increase
the level of Rab9 by reducing Rab9 degradation. The authors
concluded that cholesterol enrichment of late endosomal/lyso-
somal membranes disrupts the traﬃcking of mannose-6-phos-
phate receptors and causes the accumulation of Rab9 on these
membranes. Since Rabs play important roles in many aspects
of membrane traﬃcking, these observations indicate that the
proper targeting of a variety of proteins is likely to be impaired
in NPC deﬁcient cells. Another indication that the normal
function of Rabs is altered by NPC1 deﬁciency is the observa-
tion that overexpression of Rab7 or Rab9 in NPC1-deﬁcient
cells reduces the cholesterol accumulation in late endosomes/
lysosomes [56,57]. Furthermore, when the Rab9 content of
NPC1-deﬁcient human ﬁbroblasts and mouse cortical neurons
was increased by protein transduction, lipid storage was re-
duced [58]. Thus, increased expression of Rab7/9 appears to
partially bypass a deﬁciency of NPC1.5. Why is NPC disease primarily a neurological disorder?
An unresolved question is whether the accumulation of cho-
lesterol in NPC1-deﬁcient cells occurs secondarily to the accu-
mulation of gangliosides, or vice versa whether gangliosides
accumulate in response to the accumulation of cholesterol
[9,10,59–61]. Also unknown is whether the neurodegeneration
is caused by an accumulation of cholesterol or an accumula-
tion of gangliosides. Another key question is: are the neurolog-
ical problems characteristic of NPC disease due to an excess of
cholesterol (or gangliosides) in late endosomes/lysosomes, or
due to a deﬁciency of cholesterol (or gangliosides) at other cel-
lular locations such as the plasma membrane, endoplasmic
reticulum and/or mitochondria? The most obvious pathologi-
cal feature of NPC disease is the progressive loss of neurons,
particularly Purkinje cells in the cerebellum. Other neurologi-
cal manifestations of the disease are lipid storage, the forma-
tion of meganeurites and ectopic dendrites, and the presence
of neuroﬁbrillary tangles (reviewed in [62]). However, the
NPC1 protein is expressed in all tissues and all cell types exam-
ined to date. It is, therefore, not clear why the loss of function
of this ubiquitously expressed protein aﬀects mainly the CNS
and why neurons are particularly vulnerable.
Since the blood–brain barrier is impermeable to LDLs in the
circulation, all of the cholesterol that accumulates in NPC1-
deﬁcient brains is made endogenously within the CNS. Diets-
chy and colleagues compared the ﬂux of cholesterol in the
brains of Npc1/ and Npc1+/+ mice and found that the overall
rate of cholesterol synthesis in the brain is decreased, and the
rate of cholesterol excretion from the brain is increased, by
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terol does not depend on an increased removal of cholesterol
by 24-hydroxylation [63].
The CNS operates a lipoprotein transport system distinct
from that in the plasma. In the CNS, cholesterol is exchanged
among cells via lipoproteins that are secreted by glial cells, pri-
marily astrocytes. The most abundant apolipoprotein (apo) in
the CNS is apo E. This protein is synthesized primarily by
astrocytes, although small amounts of apo E also appear to
be made by neurons under certain conditions [64,65]. Glia-de-
rived lipoproteins are the size and density of plasma high den-
sity lipoproteins [66]. Lipoprotein particles that contain apo J
and apo A1 are also present in the CNS in smaller amounts
[67]. Apo E-containing glial lipoproteins have been shown to
promote synaptogenesis [68] and stimulate axon growth [66]
of CNS neurons. After a nerve injury, the synthesis of apo E
by glial cells increases by 150-fold [69–71]. It has been pro-
posed that apo E-containing lipoproteins secreted by astro-
cytes are taken up by adjacent neurons via receptors of the
LDL receptor superfamily [71,72]. A parallel pathway is
thought to operate in the peripheral nervous system in which
cholesterol is recovered from degenerating myelin and is deliv-
ered to neurons for axon growth and repair. Consistent with
this model, the re-utilization of cholesterol from degenerating
myelin is impaired in the peripheral nervous system of
Npc1/ mice [73].
Only a few studies have been reported on the function of
NPC1 at the molecular level in cells of the nervous system
(i.e. neurons and glia) (reviewed in [74]). As in other NPC1-
deﬁcient cells, such as ﬁbroblasts, NPC1 deﬁciency causes an
accumulation of cholesterol in cerebellar astrocytes [75]. Glial
cells (astrocytes, oligodendrocytes and microglia) comprise
approximately 90% of the cells in the brain. We suggested,
therefore, that an impaired production of lipoproteins by
NPC1-deﬁcient astrocytes might contribute to the neurological
problems of NPC disease. We tested the hypothesis that
sequestration of cholesterol in Npc1/ glial cells [75] inhibits
the generation of apo E-containing lipoproteins and/or causes
the release of defective, non-functional lipoprotein particles.
However, the amount of apo E secreted, the size of the lipo-
protein particles, and the cholesterol content of the culture
medium of Npc1/ astroglia were indistinguishable from
those of Npc1+/+ glia [75]. Moreover, in a functional assay,
apo E-containing lipoproteins from Npc1+/+ and Npc1/ glia
were equally eﬀective in stimulating axonal extension [75]. In
other studies, Scott and co-workers have demonstrated that
NPC1 function within mouse neurons per se is critical for pre-
venting neurodegeneration [76]. Thus, although these experi-
ments do not exclude the possibility of detrimental
consequences of long-term deﬁcits in the production or func-
tion of glial lipoproteins, or in other functions of glial cells,
the data indicate that the neurological problems characteristic
of NPC disease are more likely attributable to defects within
the neurons per se rather than to defects in the glial lipopro-
teins.
The function of NPC1 in neurons has also recently been
examined. Cholesterol accumulates in cell bodies of Npc1/
mouse sympathetic neurons [77]. However, the cholesterol
content of the distal axons of these neurons is diminished by
NPC deﬁciency [77]. Similarly, induction of the NPC pheno-
type by treatment of cultured hippocampal neurons with the
cholesterol transport inhibitor, U18666A, decreases the choles-terol content of axonal plasma membranes [78]. These observa-
tions are consistent with the ﬁnding that the anterograde
transport of cholesterol from cell bodies to distal axons of
Npc1/ sympathetic neurons is impaired [44]. We proposed
that the severe neurological problems in NPC disease might
occur because NPC1 has another function in neurons in addi-
tion to its established role in transporting cholesterol out of
late endosomes/lysosomes in cell bodies. Moreover, defects in
neuronal function might occur either because of lipid accumu-
lation in the cell bodies or because of a deﬁciency of cholesterol
in distal axons [77]. One defect that was detected in Npc1/
mouse embryonic striatal neurons was that the responsiveness
of these neurons to brain-derived neurotrophic factor, and a
signaling pathway initiated by the TrkB receptor, are impaired
[79].
In neurons, late endosomes/lysosomes of the degradative
pathway are thought to be restricted to the cell bodies [80].
The cholesterol that accumulates in cell bodies of NPC1-deﬁ-
cient neurons co-localizes with the late endosomal/lysosomal
marker LAMP1 (Fig. 3) [44,77]. In addition to the NPC1 pro-
tein being present in cell bodies, however, we found using indi-
rect immunoﬂuorescence [44], immunoblotting [44,81], and
adenoviral expression of a chimera of NPC1 and green ﬂuores-
cent protein [82], that NPC1 is also abundant in distal axons.
Furthermore, NPC2 is also present in both cell bodies and dis-
tal axons of mouse sympathetic neurons [81]. These ﬁndings
suggested that NPC1 and NPC2 might have neuron-speciﬁc
functions in axons.
In support of this idea, we have recently demonstrated that
NPC1 is present in recycling endosomes in pre-synaptic nerve
terminals [81]. Synaptic vesicles were isolated from the brains
of Npc1/ and Npc1+/+ mice. Although the cholesterol con-
tent of the synaptic vesicles was unaﬀected by NPC1 deﬁ-
ciency, the relative amounts of two synaptic vesicle proteins,
synaptophysin and synaptobrevin, were altered. The formation
of the synaptophysin/synaptobrevin complex is a key event in
synaptic vesicle recycling and depends on the cholesterol con-
tent of the plasma membrane [83]. Interestingly, formation of
this complex is reduced in the brains of Npc1/ mice com-
pared to Npc1+/+ mice [84]. Thus, it is possible that a reduced
content of cholesterol in the plasma membrane of axons [77]
interferes with the synaptic vesicle recycling process. Electron
microscopy of synaptosomes from the cerebellum of Npc1/
mice showed the presence of aberrantly large synaptic vesicles
[81]. Thus, NPC1 deﬁciency causes biochemical and morpho-
logical abnormalities in the pre-synaptic terminal, suggesting
that NPC1 might play a role in synaptic transmission. Perhaps
a function of NPC1 in axons is to control the cholesterol con-
tent of the nerve terminal and thereby regulate synaptic vesicle
recycling and neurotransmitter release. Although some of the
neurological problems of NPC disease (e.g. ataxia) are likely
to be caused by neuronal death (particularly of Purkinje cells),
even modest defects in synaptic transmission might contribute
to the other neurological impairments known to occur in this
disease. A recent study has reported that NPC1 deﬁciency does
not change the characteristics of ion channels or cause gross
alterations in electrophysiological properties of neurons [85].
Some intriguing histopathological similarities between
NPC disease and Alzheimer’s disease have recently emerged.
Endosomal abnormalities are characteristic of both NPC dis-
ease and Alzheimer’s disease, and cholesterol imbalance has
also been implicated in the aberrant processing of amyloid
Fig. 3. Cholesterol accumulates in late endosomes/lysosomes of cell bodies of Npc1/ mouse sympathetic neurons. Sympathetic neurons from
Npc1+/+ (upper panels) and Npc1/ (lower panels) were stained with antibodies raised against NPC1 (green) or the lysosome-associated membrane
protein-1, LAMP-1 (red). The neurons were also incubated with the cholesterol binding compound, ﬁlipin (turquoise), then examined by confocal
microscopy. In Npc1+/+ neurons, cholesterol is mainly restricted to the cell surface whereas in Npc1/ neurons cholesterol has been redistributed to,
and is sequestered in, intracellular sites that largely co-localize with LAMP-1 (merge panel). Size bar: 20 nm. (Some panels are reprinted from Karten
et al. [77] with permission.)
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[86,87]. Increased immunoreactivity to amyloid precursor pro-
tein has been observed in the brains of even very young (10-
day-old) Npc1/ mice. Moreover, the levels of Ab40 and
Ab42 are increased by NPC1-deﬁciency [88] and by treatment
of neurons with the cholesterol transport inhibitor U18666A
[89]. As in Alzheimer’s disease, neuroﬁbrillary tangles are pres-
ent in the brains of adult, and even juvenile, NPC patients
[90–92], and these tangles show the same pattern of tau hyper-
phosphorylation as occurs in brains of Alzheimer’s disease pa-
tients. Although Npc1/ mice do not develop the
neuroﬁbrillary tangles, tau is hyperphosphorylated [93–95].6. Liver disease in NPC patients
In addition to the severe neurodegeneration that occurs in
individuals with NPC disease, hepatomegaly and cholestasis
also occur perinatally in approximately 50% of individuals
with NPC disease, and some of these infants die from acute
liver failure by the age of 6 months [96]. Moreover, in
Npc1/ mice, plasma levels of alanine aminotransferase and
aspartate aminotransferase (markers of liver damage) increase
markedly after the age of 5 weeks, reaching a level 15-fold
higher than that in wild-type mice [97]. Thus, NPC1 appears
to play an important role in the liver. Indeed, the level of
expression of the NPC1 protein is higher in the liver than in
any other tissue, including the brain [98].
Furthermore, the ﬂux of lipoprotein-derived cholesterol
through the liver is greater than through any other tissue.
For example, approximately 80% of LDL-cholesterol and
nearly all of the chylomicron remnants are removed from the
plasma by the liver [14,99]. The rate of uptake of plasma
LDL cholesterol via receptor-mediated endocytosis in the liv-
ers of Npc1/ mice is the same as in Npc1+/+ mice [14]. Thus,
cholesterol from LDLs becomes sequestered in late endo-
somes/lysosomes in NPC1-deﬁcient livers: in livers of 8-week-old mice lacking functional NPC1 the cholesterol content is
approximately 10-fold higher than in wild-type mice [97].
My laboratory has recently investigated the changes in lipid
metabolism that occur in NPC1-deﬁcient mouse hepatocytes.
The cholesterol content of hepatocytes from 5-week-old
Npc1/ mice is 5-fold higher than that of Npc1+/+ hepato-
cytes. However, in marked contrast to the situation in ﬁbro-
blasts, the rate of cholesterol esteriﬁcation in hepatocytes is
increased several-fold by NPC1 deﬁciency but the rate of cho-
lesterol synthesis is not increased (A. Kulinski and J.E. Vance,
unpublished data). NPC1 deﬁciency also approximately dou-
bles the number of apo B100-containing very low density lipo-
protein particles secreted by cultured hepatocytes. Consistent
with the enhanced rate of cholesterol esteriﬁcation, the ratio
of cholesteryl esters to triacylglycerols in the very low density
lipoprotein particles secreted by Npc1/ hepatocytes is double
that in the lipoproteins secreted by Npc1+/+ hepatocytes (A.
Kulinski and J.E. Vance, unpublished data). Thus, profound
changes in lipid metabolism are induced in hepatocytes by
NPC1 deﬁciency, and some of these alterations are quite dis-
tinct from those that occur in NPC1-deﬁcient ﬁbroblasts. It
is likely that changes in lipid homeostasis induced by NPC1
deﬁciency in hepatocytes contribute to the hepatic abnormali-
ties in NPC disease.7. Potential avenues for therapeutic intervention in NPC disease
So far, no eﬀective therapies have been developed for the
treatment of NPC disease. However, the prospects of ﬁnding
a treatment for this disease have increased because of the
large body of research that has been performed during the
past 10 years in understanding the function of the NPC pro-
teins and the metabolic changes that are induced by a deﬁ-
ciency of NPC1 and NPC2. One potential strategy for
treatment of this disease is a gene therapy approach in which
the wild-type NPC gene would be delivered to NPC patients
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mains an exciting prospect, many challenges remain in the
use of gene therapy, particularly for treatment of neurological
disorders. A problem in developing therapies targeted to the
CNS is that the brain is a partially ‘‘closed’’ system in which
the blood–brain barrier restricts the import of many mole-
cules from the plasma. Therefore, therapeutic agents must
either be delivered directly into the CNS or be able to pene-
trate the blood–brain barrier.
A hallmark of NPC1 deﬁciency at the cellular level is an
aberrant accumulation of cholesterol and gangliosides in late
endosomes/lysosomes. Therefore, initial attempts to ﬁnd a
treatment for NPC disease have focused on methods that
would reduce the amount of cholesterol and/or gangliosides
in tissues, particularly in the brain. Introduction of a null
mutation in the LDL receptor into Npc1/ mice partially re-
duced the storage of cholesterol but failed to improve the neu-
rological symptoms [100]. Moreover, neither agents that lower
plasma cholesterol nor dietary measures have been successful
in slowing the neurological progression of the disease (re-
viewed in [101]). The accumulation of gangliosides in tissues
of NPC1-deﬁcient humans and mice suggested that strategies
to reduce the amounts of these lipids in the brain might be a
viable therapeutic strategy for treatment of NPC disease. Thus,
Npc1/ mice were crossed with mice that lacked N-acetylga-
lactosamine transferase; the double knock-out mice were un-
able to synthesize the ganglioside, GM2. Even though these
mice completely lacked the ganglioside GM2 their life-span
was not increased. These observations indicate that the accu-
mulation of GM2 ganglioside is not the cause of the neuropa-
thology in Npc1/ mice. Nevertheless, NPC1-deﬁcient mice
were administered N-butyldeoxynojirimycin, a potent inhibitor
of the ﬁrst step in the synthesis of all the glycosphingolipids,
including gangliosides. The lifespan of these mice was extended
by approximately 20% and some of the neurological symptoms
were delayed [102]. These ﬁndings have culminated in a clinical
trial that is currently in progress using this inhibitor in children
with NPC disease.
Another promising approach for treatment of NPC disease
came from the ﬁnding that the levels of neurosteroids, and
the enzyme activities involved in the synthesis of these steroids,
are signiﬁcantly reduced in the brains of NPC1-deﬁcient mice,
particularly in the cerebellum [103]. When one of these neuros-
teroids, allopregnanolone, was administered to neonatal
Npc1/ mice the onset of neurological symptoms was delayed
and the lifespan of the mice was increased from 67 days to 147
days [103]. Although the mechanism by which neurosteroids
ameliorate the pathophysiology of NPC disease is not yet
known, these striking results suggest that a treatment for
NPC disease based on neurosteroid therapy might be beneﬁ-
cial.
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